Cadila Healthcare informs about press release

12 Dec 2018 Evaluate

Cadila Healthcare has informed that as per the USFDA letter with reference to the company's supplemental abbreviated new drug application (sANDA) received for review on August 20, 2018, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Ranitidine Injection USP, 25 mg/mL, 2 mL Single dose vials and 6 mL Multi-dose vials, the sANDA approval has been granted by the USFDA for a new fill size, 40 mL Pharmacy Bulk Package which was inadvertently mentioned as 25 mg/mL, 2 mL Single dose vials and 6 mL Multi-dose vials in the press note titled Liva Pharmaceuticals receives approval from the USFDA for its supplemental abbreviated new drug application (sANDA), Ranitidine Injection USP released by the company yesterday, December 11, 2018.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×